These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22546242)

  • 1. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
    Raza A; Galili N; Mulford D; Smith SE; Brown GL; Steensma DP; Lyons RM; Boccia R; Sekeres MA; Garcia-Manero G; Mesa RA
    J Hematol Oncol; 2012 Apr; 5():18. PubMed ID: 22546242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
    Raza A; Galili N; Smith SE; Godwin J; Boccia RV; Myint H; Mahadevan D; Mulford D; Rarick M; Brown GL; Schaar D; Faderl S; Komrokji RS; List AF; Sekeres M
    Cancer; 2012 Apr; 118(8):2138-47. PubMed ID: 21887679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
    Raza A; Galili N; Callander N; Ochoa L; Piro L; Emanuel P; Williams S; Burris H; Faderl S; Estrov Z; Curtin P; Larson RA; Keck JG; Jones M; Meng L; Brown GL
    J Hematol Oncol; 2009 May; 2():20. PubMed ID: 19439093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure.
    Quddus F; Clima J; Seedham H; Sajjad G; Galili N; Raza A
    J Hematol Oncol; 2010 Apr; 3():16. PubMed ID: 20416051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.
    Raza A; Galili N; Smith S; Godwin J; Lancet J; Melchert M; Jones M; Keck JG; Meng L; Brown GL; List A
    Blood; 2009 Jun; 113(26):6533-40. PubMed ID: 19398716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
    Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
    PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
    Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
    Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
    Syed YY; Scott LJ
    Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
    Toma A; Kosmider O; Chevret S; Delaunay J; Stamatoullas A; Rose C; Beyne-Rauzy O; Banos A; Guerci-Bresler A; Wickenhauser S; Caillot D; Laribi K; De Renzis B; Bordessoule D; Gardin C; Slama B; Sanhes L; Gruson B; Cony-Makhoul P; Chouffi B; Salanoubat C; Benramdane R; Legros L; Wattel E; Tertian G; Bouabdallah K; Guilhot F; Taksin AL; Cheze S; Maloum K; Nimuboma S; Soussain C; Isnard F; Gyan E; Petit R; Lejeune J; Sardnal V; Renneville A; Preudhomme C; Fontenay M; Fenaux P; Dreyfus F
    Leukemia; 2016 Apr; 30(4):897-905. PubMed ID: 26500139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
    Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Matsuda A; Tohyama K; Taniwaki M; Takeshita K; Takatoku M; Ozawa K
    Int J Hematol; 2009 Oct; 90(3):353-360. PubMed ID: 19705057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
    Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
    Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
    Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
    Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.
    Díez-Campelo M; López-Cadenas F; Xicoy B; Lumbreras E; González T; Del Rey González M; Sánchez-García J; Coll Jordà R; Slama B; Hernández-Rivas JÁ; Thepot S; Bernal T; Guerci-Bresler A; Bargay J; Amigo ML; Preudhomme C; Fenwarth L; Platzbecker U; Götze KS; Arar A; Toribio S; Del Cañizo C; Hernández-Rivas JM; Fenaux P
    Lancet Haematol; 2024 Sep; 11(9):e659-e670. PubMed ID: 39033767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
    Galili N; Tamayo P; Botvinnik OB; Mesirov JP; Brooks MR; Brown G; Raza A
    J Hematol Oncol; 2012 May; 5():20. PubMed ID: 22559819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.